

## Letter to the Editor

**Routine ACEs screening is NOT recommended**

John D. McLennan MD PhD FRCPC<sup>1,2</sup>, Harriet L. MacMillan CM MD MSc FRCPC<sup>3,4,5</sup>, Tracie O. Afifi MSc PhD<sup>6</sup>, Jill McTavish MLIS PhD<sup>4,5</sup>, Andrea Gonzalez MA PhD<sup>4,5</sup>, Charlotte Waddell MSc MD CCFP FRCPC<sup>7</sup>

<sup>1</sup>Department of Pediatrics, University of Calgary, Calgary, Alberta; <sup>2</sup>Children's Hospital of Eastern Ontario-Research Institute, Ottawa, Ontario; <sup>3</sup>Department of Pediatrics, McMaster University, Hamilton, Ontario; <sup>4</sup>Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, Ontario; <sup>5</sup>Offord Centre for Child Studies, Hamilton, Ontario; <sup>6</sup>Departments of Community Health Sciences and Psychiatry, University of Manitoba, Winnipeg, Manitoba; <sup>7</sup>Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia

**Correspondence:** John D. McLennan, CHEO-RI, 401 Smyth Road, Ottawa, Ontario K1H 8L1. Telephone 613-738-7600, fax 613-738-4210, e-mail [jmclennan@cheo.on.ca](mailto:jmclennan@cheo.on.ca)

**Letter to the Editor in response to the article:** Watson P. How to screen for ACEs in an efficient, sensitive, and effective manner. *Paediatr Child Health*. 2018; 1–2. doi:10.1093/pch/pxy146

An increasing number of stakeholders are calling for the implementation of universal screening for adverse childhood experiences (ACEs). While there is little doubt that ACEs increase the likelihood of negative sequelae, this does not automatically translate to benefits from universal ACEs screening. This is the situation for other proposed universal screenings. For example, while developmental delays in childhood are important, the Canadian Task Force on Preventive Health Care recommended against universal screening for such delays in 1-to-4-year-olds given the lack of evidence that commonly-used screening tools would identify otherwise unrecognized cases, and the likelihood of a high proportion of false positives (1). Similarly, while child maltreatment is a serious problem (as well as a core component of ACEs), the limited evidence of benefits of screening resulted in recent guidance from the updated World Health Organization Mental Health Gap Action Programme NOT recommending universal screening for child maltreatment (2).

Finkelhor and others have identified multiple problems with the recommendation for widespread ACEs screening including the lack of evidence-based programs that map onto high ACEs scores and the potential adverse impacts of false positives, among others (3). As well, in systematically examining the research evidence for ACEs screening using recommended health screening criteria (4), none of the key criteria were met (5). In particular, screening without a clear connection to available and effective interventions may be harmful. Importantly, while there are some evidence-based

interventions for those that experience negative sequelae from ACEs (e.g., post-traumatic stress disorder), there are no evidence-based interventions tied to scores on an ACEs checklist. Furthermore, there is no compelling evidence that a coherent and effective pathway to accessing evidence-based child and parent mental health interventions would result from guidance from 'yes/no' responses on a checklist of ACEs. Given these concerns, we think it is inappropriate to engage in universal ACEs screening at this time. Decisions to implement universal ACEs screening should be based on rigorous evaluations to determine if benefits outweigh harms. A formal review by the Canadian Task Force on Preventive Health Care could inform this critical question.

While Dr. Watson's article (6) may serve to raise awareness of the importance of adverse exposures in childhood, we disagree with her recommendation to implement ACEs screening in primary and paediatric care. We also disagree that the current ACEs instrument has been adequately validated and that ACEs screening meets screening criteria. In conclusion, we believe that at this time there is no evidence to justify the rollout of ACEs screening in clinical and public health practice.

**References**

1. Canadian Task Force on Preventative Health Care. Recommendations on screening for developmental delay. *Can Med Assoc J*. 2016;188(8):S79–87.
2. World Health Organization. Update of the mental health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. Geneva,

- Switzerland: World Health Organization; 2015. <[http://apps.who.int/iris/bitstream/10665/204132/1/9789241549417\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/204132/1/9789241549417_eng.pdf?ua=1)>
3. Finkelhor D. Screening for adverse childhood experiences (ACEs): Cautions and suggestions. *Child Abuse Negl* 2018;85:174–9.
  4. Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. Consolidated principles for screening based on a systematic review and consensus process. *CMAJ* 2018;190(14):E422–9.
  5. McLennan JD, McTavish J, MacMillan HL. Routine screening of ACEs: Should we or shouldn't we? In: Asmundson GJG, Afifi TO, eds. *Adverse Childhood Experiences (ACEs): Using Evidence to Advance Research, Practice, Policy and Prevention*. San Diego: Academic Press; Forthcoming 2019; (pp. xxx–xxx).
  6. Watson P. How to screen for ACEs in an efficient, sensitive, and effective manner. *Paediatr Child Health* 2019;24(1):37–8.